A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of CB1 Antagonist ANEB-001 in Healthy Occasional Cannabis Users in a THC Challenge Test.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 154
- 试验地点
- 1
- 主要终点
- Postural stability
研究概览
简要总结
The aim of this study is to investigate whether ANEB-001 effectively penetrates the brain and inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis. This randomized, placebo-controlled, double-blind study is designed as a proof-of-pharmacology and dose finding study for the antagonistic effect of ANEB-001 during a THC challenge. Results of this study will inform the future potential use of ANEB-001 as an emergency treatment for acute cannabinoid intoxication.
详细描述
This study will evaluate whether ANEB-001 effectively inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC). All cohorts in part A and B of the study will be randomized, double-blind and placebo-controlled. Randomization is deemed appropriate to avoid selection bias for active compound or placebo treatment. A double-blind and placebo-controlled design is deemed appropriate because of the safety, tolerability and pharmacodynamic assessments that will be performed in this study. By double-blinding the study, bias arising from study subject's or investigator's knowledge about treatment assignment is avoided. Part C does not include a placebo group and will therefore not be blinded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent prior to any study-mandated procedure
- •BMI between 18 and 30 kg/m2
- •Minimum weight 50 kg
- •Occasional cannabis user
排除标准
- •Evidence of active or chronic condition that could interfere with, or which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator
- •Clinically significant abnormalities, as judged by the investigator
- •Positive Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody at screening
- •Systolic blood pressure greater than 130 or less than 90 mm Hg and diastolic blood pressure greater than 95 or less than 50 mm Hg at screening Abnormal findings in the resting electrocardiogram
- •Use of any medications within 7 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions are paracetamol and ibuprofen and topical medications.
- •Use of any vitamin, mineral, herbal and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer)
- •Participation in an investigational drug or device study (last dosing of previous study was within 90 days prior to first dosing of this study)
- •History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units alcohol per week, drug abuse, or regular user of sedatives, hypnotics, tranquilizers, or any other addictive agent other than recreative use of THC
- •Positive test for drugs of abuse (other than THC) at screening.
- •Positive test for drugs of abuse pre-dose
- •Clinically significant suicidal ideation in the past 5 years as judged by the investigator or any life-time suicide attempts
- •History of cannabis-induced psychosis, schizophrenia or other clinically relevant psychiatric disorders, as judged by the investigator.
- •History of a clinically significant mood disorder, including but not limited to major depressive disorder, as judged by the investigator.
研究组 & 干预措施
Part B - Cohort 3 - Placebo
Subjects receive 21 mg THC and 1 hour later, placebo
干预措施: Placebo (Drug)
Part B - Cohort 3 - ANEB-001
Subjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001
干预措施: ANEB-001 (Drug)
Part A - ANEB-001
Subjects receive THC and varying amounts of ANEB-001
干预措施: ANEB-001 (Drug)
Part A - Placebo
Subjects receive THC and placebo
干预措施: Placebo (Drug)
Part B - Cohort 1 - ANEB-001
Subjects receive 21 mg of THC and 30 mg of ANEB-001
干预措施: ANEB-001 (Drug)
Part B - Cohort 1 - Placebo
Subjects receive 21 mg of THC and placebo
干预措施: Placebo (Drug)
Part B - Cohort 2 - ANEB-001
Subjects receive 21 mg of THC and 10 mg of ANEB-001
干预措施: ANEB-001 (Drug)
Part B - Cohort 2 - Placebo
Subjects receive 21 mg of THC and placebo
干预措施: Placebo (Drug)
Part B - Cohort 4 - ANEB-001
Subjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001
干预措施: ANEB-001 (Drug)
Part B - Cohort 4 - Placebo
Subjects receive 40 mg of THC and 1 hour later, placebo
干预措施: Placebo (Drug)
Part B - Cohort 5 - ANEB-001
Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
干预措施: ANEB-001 (Drug)
Part B - Cohort 5 - Placebo
Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
干预措施: Placebo (Drug)
Part B - Cohort 6 - ANEB-001
Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001
干预措施: ANEB-001 (Drug)
Part B - Cohort 6 - Placebo
Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo
干预措施: Placebo (Drug)
Part C - Cohort 7 - ANEB-001
Subjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001
干预措施: ANEB-001 (Drug)
Part C - Cohort 8 - ANEB-001
Subjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001
干预措施: ANEB-001 (Drug)
结局指标
主要结局
Postural stability
时间窗: Day 1
Body sway (mm);
Subjective Feeling High
时间窗: Day 1
Feeling High on a visual analog scale (mm)
Heart Rate
时间窗: Day 1
Heart Rate in beats/min
Subjective Alertness
时间窗: Day 1
Alertness on a visual analog scale (mm)
次要结局
- Subjective Mood(Day 1)
- Visual Verbal Learning Test (VVLT)(Day 1)
- Alternate Finger Tapping (AFT)(Day 1)
- Basic Symptom Inventory (BSI)(Day 1)
- Feeling of Drug Effect(Day 1)
- Brief Psychiatric Rating Scale (BPRS)(Day 1)
- Subjective Calmness(Day 1)
- Symbol Digit Substitution Test (SDST)(Day 1)
- Timed Up-and-Go test (TUG)(Day 1)
- Clinical Global Impression of Severity (CGIS)(Day 1)